BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 26802049)

  • 1. Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia.
    Cheng CK; Chan NP; Wan TS; Lam LY; Cheung CH; Wong TH; Ip RK; Wong RS; Ng MH
    Haematologica; 2016 Apr; 101(4):448-57. PubMed ID: 26802049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
    Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
    Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
    Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
    Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter DNA methylation and expression levels of HOXA4, HOXA5 and MEIS1 in acute myeloid leukemia.
    Musialik E; Bujko M; Kober P; Grygorowicz MA; Libura M; Przestrzelska M; Juszczyński P; Borg K; Florek I; Jakóbczyk M; Siedlecki JA
    Mol Med Rep; 2015 May; 11(5):3948-54. PubMed ID: 25585874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
    Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES
    Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of CCAAT/Enhancer Binding Protein (C/EBP) Alpha (CEBPA) and Runt-Related Transcription Factor 1 (RUNX1) Expression in Patients with De Novo Acute Myeloid Leukemia.
    Salarpour F; Goudarzipour K; Mohammadi MH; Ahmadzadeh A; Faraahi S; Farsani MA
    Ann Hum Genet; 2017 Nov; 81(6):276-283. PubMed ID: 28895127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis.
    Guo H; Ma O; Speck NA; Friedman AD
    Blood; 2012 May; 119(19):4408-18. PubMed ID: 22451420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia.
    Simeoni F; Romero-Camarero I; Camera F; Amaral FMR; Sinclair OJ; Papachristou EK; Spencer GJ; Lie-A-Ling M; Lacaud G; Wiseman DH; Carroll JS; Somervaille TCP
    Cell Rep; 2021 Sep; 36(12):109725. PubMed ID: 34551306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia.
    Bluteau D; Gilles L; Hilpert M; Antony-Debré I; James C; Debili N; Camara-Clayette V; Wagner-Ballon O; Cordette-Lagarde V; Robert T; Ripoche H; Gonin P; Swierczek S; Prchal J; Vainchenker W; Favier R; Raslova H
    Blood; 2011 Dec; 118(24):6310-20. PubMed ID: 21725049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell.
    Shima T; Miyamoto T; Kikushige Y; Yuda J; Tochigi T; Yoshimoto G; Kato K; Takenaka K; Iwasaki H; Mizuno S; Goto N; Akashi K
    Exp Hematol; 2014 Nov; 42(11):955-65.e1-5. PubMed ID: 25101977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs.
    Gerritsen M; Yi G; Tijchon E; Kuster J; Schuringa JJ; Martens JHA; Vellenga E
    Blood Adv; 2019 Feb; 3(3):320-332. PubMed ID: 30709863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
    Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
    Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secreted-frizzled related protein 1 is a transcriptional repression target of the t(8;21) fusion protein in acute myeloid leukemia.
    Cheng CK; Li L; Cheng SH; Ng K; Chan NP; Ip RK; Wong RS; Shing MM; Li CK; Ng MH
    Blood; 2011 Dec; 118(25):6638-48. PubMed ID: 22031861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.
    Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK
    Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation.
    Hartmann L; Dutta S; Opatz S; Vosberg S; Reiter K; Leubolt G; Metzeler KH; Herold T; Bamopoulos SA; Bräundl K; Zellmeier E; Ksienzyk B; Konstandin NP; Schneider S; Hopfner KP; Graf A; Krebs S; Blum H; Middeke JM; Stölzel F; Thiede C; Wolf S; Bohlander SK; Preiss C; Chen-Wichmann L; Wichmann C; Sauerland MC; Büchner T; Berdel WE; Wörmann BJ; Braess J; Hiddemann W; Spiekermann K; Greif PA
    Nat Commun; 2016 Jun; 7():11733. PubMed ID: 27252013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis.
    Libura M; Pawełczyk M; Florek I; Matiakowska K; Jaźwiec B; Borg K; Solarska I; Zawada M; Czekalska S; Libura J; Salamanczuk Z; Jakóbczyk M; Mucha B; Duszeńko E; Soszyńska K; Karabin K; Piątkowska-Jakubas B; Całbecka M; Gajkowska-Kulig J; Gadomska G; Kiełbiński M; Ejduk A; Kata D; Grosicki S; Kyrcz-Krzemień S; Warzocha K; Kuliczkowski K; Skotnicki A; Jęrzejczak WW; Haus O
    Blood Cells Mol Dis; 2015 Dec; 55(4):284-92. PubMed ID: 26460249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RUNX1 inhibits proliferation and induces apoptosis of t(8;21) leukemia cells
    Liu S; Xing Y; Lu W; Li S; Tian Z; Xing H; Tang K; Xu Y; Rao Q; Wang M; Wang J
    Haematologica; 2019 Aug; 104(8):1597-1607. PubMed ID: 30792202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.
    Kiehlmeier S; Rafiee MR; Bakr A; Mika J; Kruse S; Müller J; Schweiggert S; Herrmann C; Sigismondo G; Schmezer P; Krijgsveld J; Gröschel S
    Leukemia; 2021 Nov; 35(11):3127-3138. PubMed ID: 33911178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.